Drug repurposing is a promising strategy to find new usage for existing drugs outside of their original purpose. We have recently developed a computational framework ASGARD that employs single cell RNA-sequencing (scRNA-seq) to repurpose drugs. However, scRNA-seq lacks the spatial information of the tissue, an important determinant of the heterogeneity within the tissue micro-environment. In this paper, we propose Spatial Transcriptomics to Aid Drug-reposition Recommendation (STADS) framework, a new drug repurposing computational framework that employs Spatial Transcriptomics (ST) datasets with gene expression in situ. STADS reduces the ST gene expression by spatially-aware embedding, integrates multiple healthy and diseased samples, identifies the matched spatial domains between disease and controls, then repurposes drugs by a novel drug score that considers differentially expressed genes between disease and control samples among all matched spatial domains. We apply STADS to a ST dataset of patients with Hepatocellular Carcinoma and demonstrate its superior performance to ASGARD. STADS is a promising personalized drug repurposing prediction method using ST data.

Motif discovery and characterization are important for gene regulation analysis. The lack of intuitive and integrative web servers impedes the effective use of motifs. Most motif discovery web tools are either not designed for non-expert users or lacking optimization steps when using default settings. Here we describe bipartite motifs learning (BML), a parameter-free web server that provides a user-friendly portal for online discovery and analysis of sequence motifs, using high-throughput sequencing data as the input. BML utilizes both position weight matrix and dinucleotide weight matrix, the latter of which enables the expression of the interdependencies of neighboring bases. With input parameters concerning the motifs are given, the BML achieves significantly higher accuracy than other available tools for motif finding. When no parameters are given by non-expert users, unlike other tools, BML employs a learning method to identify motifs automatically and achieve accuracy comparable to the scenario where the parameters are set. The BML web server is freely available at http://motif.t-ridership.com/ (https://github.com/Mohammad-Vahed/BML).

SUMMARY: Cox-nnet is a neural-network-based prognosis prediction method, originally applied to genomics data. Here, we propose the version 2 of Cox-nnet, with significant improvement on efficiency and interpretability, making it suitable to predict prognosis based on large-scale population data, including those electronic medical records (EMR) datasets. We also add permutation-based feature importance scores and the direction of feature coefficients. When applied on a kidney transplantation dataset, Cox-nnet v2.0 reduces the training time of Cox-nnet up to 32-folds (n =10 000) and achieves better prediction accuracy than Cox-PH (P<0.05). It also achieves similarly superior performance on a publicly available SUPPORT data (n=8000). The high efficiency and accuracy make Cox-nnet v2.0 a desirable method for survival prediction in large-scale EMR data. AVAILABILITY AND IMPLEMENTATION: Cox-nnet v2.0 is freely available to the public at https://github.com/lanagarmire/Cox-nnet-v2.0. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Artificial neural networks (ANN) are computing architectures with many interconnections of simple neural-inspired computing elements, and have been applied to biomedical fields such as imaging analysis and diagnosis. We have developed a new ANN framework called Cox-nnet to predict patient prognosis from high throughput transcriptomics data. In 10 TCGA RNA-Seq data sets, Cox-nnet achieves the same or better predictive accuracy compared to other methods, including Cox-proportional hazards regression (with LASSO, ridge, and mimimax concave penalty), Random Forests Survival and CoxBoost. Cox-nnet also reveals richer biological information, at both the pathway and gene levels. The outputs from the hidden layer node provide an alternative approach for survival-sensitive dimension reduction. In summary, we have developed a new method for accurate and efficient prognosis prediction on high throughput data, with functional biological insights. The source code is freely available at https://github.com/lanagarmire/cox-nnet.

BACKGROUND: Epigenetic alterations are known to correlate with changes in gene expression among various diseases including cancers. However, quantitative models that accurately predict the up or down regulation of gene expression are currently lacking. METHODS: A new machine learning-based method of gene expression prediction is developed in the context of lung cancer. This method uses the Illumina Infinium HumanMethylation450K Beadchip CpG methylation array data from paired lung cancer and adjacent normal tissues in The Cancer Genome Atlas (TCGA) and histone modification marker CHIP-Seq data from the ENCODE project, to predict the differential expression of RNA-Seq data in TCGA lung cancers. It considers a comprehensive list of 1424 features spanning the four categories of CpG methylation, histone H3 methylation modification, nucleotide composition, and conservation. Various feature selection and classification methods are compared to select the best model over 10-fold cross-validation in the training data set. RESULTS: A best model comprising 67 features is chosen by ReliefF based feature selection and random forest classification method, with AUC = 0.864 from the 10-fold cross-validation of the training set and AUC = 0.836 from the testing set. The selected features cover all four data types, with histone H3 methylation modification (32 features) and CpG methylation (15 features) being most abundant. Among the dropping-off tests of individual data-type based features, removal of CpG methylation feature leads to the most reduction in model performance. In the best model, 19 selected features are from the promoter regions (TSS200 and TSS1500), highest among all locations relative to transcripts. Sequential dropping-off of CpG methylation features relative to different regions on the protein coding transcripts shows that promoter regions contribute most significantly to the accurate prediction of gene expression. CONCLUSIONS: By considering a comprehensive list of epigenomic and genomic features, we have constructed an accurate model to predict transcriptomic differential expression, exemplified in lung cancer.

Breast cancer is the most common malignancy in women worldwide. With the increasing awareness of heterogeneity in breast cancers, better prediction of breast cancer prognosis is much needed for more personalized treatment and disease management. Towards this goal, we have developed a novel computational model for breast cancer prognosis by combining the Pathway Deregulation Score (PDS) based pathifier algorithm, Cox regression and L1-LASSO penalization method. We trained the model on a set of 236 patients with gene expression data and clinical information, and validated the performance on three diversified testing data sets of 606 patients. To evaluate the performance of the model, we conducted survival analysis of the dichotomized groups, and compared the areas under the curve based on the binary classification. The resulting prognosis genomic model is composed of fifteen pathways (e.g., P53 pathway) that had previously reported cancer relevance, and it successfully differentiated relapse in the training set (log rank p-value = 6.25e-12) and three testing data sets (log rank p-value < 0.0005). Moreover, the pathway-based genomic models consistently performed better than gene-based models on all four data sets. We also find strong evidence that combining genomic information with clinical information improved the p-values of prognosis prediction by at least three orders of magnitude in comparison to using either genomic or clinical information alone. In summary, we propose a novel prognosis model that harnesses the pathway-based dysregulation as well as valuable clinical information. The selected pathways in our prognosis model are promising targets for therapeutic intervention.

We present a global clustering approach to identify putative intergenic non-coding RNAs based on the RNA polymerase II and Histone 3 lysine 4 trimethylation signatures. Both of these signatures are processed from the digital sequencing tags produced by chromatin immunoprecipitation, a high-throughput massively parallel sequencing (ChIP-Seq) technology. Our method compares favorably to the comparison method. We characterize the intergenic non-coding RNAs to have conservative promoters. We predict that these nc-RNAs are related to metabolic process without lipopolysaccharides (LPS) treatment, but shift towards developmental and immune-related functions with LPS treatment. We demonstrate that more intergenic nc-RNAs respond positively to LPS treatment, rather than negatively. Using QPCR, we experimentally validate 8 out of 11 nc-RNA regions respond to LPS treatment as predicted by the computational method.